Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07.Submission of Matters to a Vote of Security Holders.

Blueprint Medicines Corporation (the Company) held its annual
meeting of stockholders on June 20, 2017.The following is a
summary of the matters voted on at the meeting.

1.

The Companys stockholders elected Alexis Borisy, Lonnel
Coats and Charles A. Rowland, Jr. as Class II directors,
each to serve until the 2020 annual meeting of
stockholders and until his successor has been duly
elected and qualified.The results of the stockholders
vote with respect to the election of such Class II
directors were as follows:

For

Withheld

Broker Non-Votes

Alexis Borisy

25,930,858 7,394,588 2,528,982

Lonnel Coats

27,545,261 5,780,185 2,528,982

Charles A. Rowland, Jr.

27,823,540 5,501,906 2,528,982

2.

The Companys stockholders ratified the appointment of
Ernst Young LLP as the Companys independent registered
public accounting for the fiscal year ending December 31,
2017. The results of the stockholders vote with respect
to such ratification were as follows:

For

Against

Abstain

35,793,487 54,981 5,960

2


About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).